Leqembi

Biogen's monoclonal antibody for Alzheimer's disease.

Manila folder with CONFIDENTIAL printed on it in red
CRO

Alzheimer's trials withheld brain injury risk disclosures: NYT

Between both companies, more than 560 people joined trials without being told they had a heightened risk of dangerous side effects, NYT reports.
Darren Incorvaia Oct 24, 2024 11:33am
alzheimers brain neurodegenerative memory head

AbbVie axes Alzheimer's program amid 'evolving landscape'

Jul 25, 2024 10:49am
brain alzheimers dementia neuroscience gears thought think

Lilly's donanemab sails through FDA meeting with 2 yes votes

Jun 10, 2024 5:11pm
brain amyloid alzheimers strings detailed web complicated thought

FDA lays out donanemab concerns, Lilly vigorously defends safety

Jun 6, 2024 10:55am
slipstream contrails aircraft airplanes sky fly miss cross

Lilly glides out of Leqembi slipstream with FDA meeting request

Apr 17, 2024 5:00am
alzheimers brain neurodegenerative memory head

FDA revises guidance on predicting Alzheimer's drug benefits

Mar 12, 2024 7:40am